Skip to main content
S&P 5007,811.54+0.59%DOW51,654.95+0.83%NASDAQ27,366.17+0.64%BTC$82,516.00+0.84%ETH$2,488.45+0.36%GOLD$4,220.30+1.52%OIL$91.66+0.19%
Smart Investors Daily
SID Premium
TA

NYSE · TAK

Takeda Pharmaceutical Company Limited

Healthcare · Drug Manufacturers - Specialty & Generic

$18.73

Up+$0.21 (+1.13%)

Updated Oct 10, 2026, 6:17 PM

SID Score

5.7/10

Composite research score

Smart Money

58/100

Neutral

Market cap
45.42B
P/E ratio
50.83
Dividend yield
3.53%
52-week range
$12.99 – $19.10
Volume
2.04M
Avg. volume
2.78M

Price performance · TAK

TAK price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 9, 2026

TAK closed at $18.73 after 21 trading sessions, up 2.57% for the selected period.

Last close
$18.73
Period change
+2.57%
Period low
$17.81
Period high
$19.05
Daily close
View OHLC price history
TAK OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 9, 2026$18.37$18.755$18.37$18.732.04M
Oct 8, 2026$18.39$18.52$18.215$18.523.51M
Oct 7, 2026$18.14$18.4551$18.14$18.372.56M
Oct 6, 2026$17.97$18.179$17.955$18.103.1M
Oct 5, 2026$17.78$17.91$17.75$17.813.4M
Oct 2, 2026$17.85$17.89$17.78$17.862.13M
Oct 1, 2026$18.07$18.13$17.86$17.862.4M
Sep 30, 2026$18.46$18.46$18.185$18.192.1M
Sep 29, 2026$18.56$18.575$18.3701$18.512.42M
Sep 28, 2026$18.76$19.00$18.645$18.902.06M
Sep 25, 2026$18.82$18.91$18.765$18.862.74M
Sep 24, 2026$18.55$18.735$18.51$18.593.26M
Sep 23, 2026$18.86$18.98$18.78$18.812.61M
Sep 22, 2026$18.92$19.045$18.81$18.951.4M
Sep 21, 2026$18.98$18.99$18.84$18.891.76M
Sep 18, 2026$18.80$19.01$18.80$18.912.96M
Sep 17, 2026$19.02$19.10$19.00$19.052.71M
Sep 16, 2026$18.75$18.825$18.595$18.642.95M
Sep 15, 2026$18.74$18.765$18.61$18.702.68M
Sep 14, 2026$18.56$18.70$18.54$18.602.36M
Sep 11, 2026$18.38$18.445$18.20$18.262.15M

Latest TAK news

The latest Smart Investors Daily articles mentioning TAK.

Stock researchCompany · Overview

TAK research

Overview

Company profile and research snapshot.

Company profile

Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
TAK recent ratings
DateFirmRatingTarget
Mar 11, 2020JP MorganOverweight—
Nov 1, 2019Cowen & Co.Market Perform—
Sep 24, 2019JefferiesBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Oct 1, 2026

Takeda (TSE:4502) Stock Looks Below Fair Value Even After A 120% Run

Takeda Pharmaceutical has delivered a strong multi year run, and recent drug trial headlines now put a sharper spotlight on whether the current share price lines up with its sales base. For investors watching Takeda stock today, the core issue is how that performance and pipeline story stack up against what the business is actually generating in revenue. Takeda shares are up 120.5% over 5 years, which raises the question of how much of that gain is supported by the company’s sales...

Yahoo · Oct 1, 2026

Corus International Receives $6.4 Million Grant From Takeda to Reduce Climate-Related Health Risks in Nepal

WASHINGTON & TOKYO, October 01, 2026--Corus International announced it has received a $6.4 million grant from Takeda Pharmaceutical Company Limited to help reduce climate-related health risks in Nepal. Corus was selected as part of Takeda’s 2026 Global Corporate Social Responsibility (CSR) program. The company issued a press release announcing all the awardees and the scope of its program.

Yahoo · Oct 1, 2026

Will Zasocitinib’s Phase 3 Outperformance Reshape Takeda Pharmaceutical's (TSE:4502) Immunology-Driven Pipeline Narrative

Takeda Pharmaceutical recently reported Phase 3 data showing that its investigational oral TYK2 inhibitor, zasocitinib (TAK-279), achieved statistically superior complete skin clearance versus deucravacitinib and outperformed apremilast in adults with moderate-to-severe plaque psoriasis, with results presented at the 2026 European Academy of Dermatology & Venereology Congress. A particularly important finding is that zasocitinib delivered more than 2.5 times as many patients with complete...

Yahoo · Sep 30, 2026

Takeda Pharmaceutical (TSE:4502) Could Be 13% Undervalued On Strong Phase 3 Psoriasis Data

Takeda Pharmaceutical (TSE:4502) has put its psoriasis pipeline in the spotlight after new Phase 3 LATITUDE data showed that investigational pill zasocitinib outperformed deucravacitinib on skin clearance measures in adults with moderate to severe plaque psoriasis. Taken together with Takeda Pharmaceutical’s oncology pipeline updates and recent leadership change in Spain, the psoriasis data arrives during a period of strong market performance, with the share price up 17.6% year to date and a...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By